Table 1.

Cox regression analysis of disease-free and overall survival in relation to median p27 and cyclin E expression (n = 2020)^*

Marker	Unadjusted HR (95% CI)	Adjusted† HR (95% CI)	Adjusted‡ HR (95% CI)	Adjusted/negative receptors§ HR (95% CI)	Adjusted/positive receptors§ HR (95% CI)
Disease-free survival
p27	1.31 (1.10 to 1.57)	1.32 (1.10 to 1.57)	1.18 (0.98 to 1.42)	1.06 (0.81 to 1.39)	1.27 (0.99 to 1.63)
cyclin E	1.09 (0.92 to 1.29)	1.13 (0.95 to 1.34)	1.02 (0.85 to 1.22)	0.95 (0.74 to 1.21)	1.13 (0.88 to 1.46)
Overall survival
p27	1.50 (1.21 to 1.86)	1.51 (1.22 to 1.87)	1.31 (1.05 to 1.64)	1.19 (0.86 to 1.64)	1.42 (1.05 to 1.94)
cyclin E	1.12 (0.91 to 1.38)	1.17 (0.95 to 1.44)	1.03 (0.83 to 1.27)	0.87 (0.65 to 1.16)	1.25 (0.92 to 1.71)

^*HR = hazard ratio; CI = confidence interval. Overall survival was defined as the time to death from any cause. Disease-free survival was defined as the time to first recurrence (local, regional, or distant), new primary cancer in the contralateral breast, or death due to any cause.

^†Analyses were adjusted for tumor size (<2 cm, 2–5 cm, or >5 cm), number of positive lymph nodes (0, 1, 2, or 3), menopausal status, and randomized treatment but not receptor status.

^‡Analyses were adjusted for tumor size (<2 cm, 2–5 cm, or >5 cm), number of positive lymph nodes (0, 1, 2, or 3), menopausal status, randomized treatment, and receptor status (both estrogen receptor and progesterone receptor negative vs. either positive).

^§Analyses were adjusted for tumor size, number of positive lymph nodes, menopausal status, and treatment and then separately analyzed by receptor status.